Cantargia AB provided an update on the progress in the development of a manufacturing process for CAN10 and the clinical trial preparations, with minor adjustments to the timeline. Development of a manufacturing process for CAN10 has been successful and high yields have been obtained in initial productions. Due to the high demand for COVID-19 vaccines, there is global shortage of raw materials and consumables required for manufacturing of clinical-grade substances. Therefore, start of the production of CAN10 for use in clinical trials has been moved from Fourth Quarter 2021 to First Quarter 2022. Consequently, the first clinical study for CAN10 is planned to start during Third Quarter 2022. Cantargia develops antibody-based pharmaceuticals against interleukin-1 receptor accessory protein (IL1RAP). The lead project CAN04 (nadunolimab) is in phase IIa clinical development for treatment of cancer while Cantargia's second project, CAN10, is in preclinical development for inflammatory and autoimmune disease. Cantargia previously communicated that a manufacturing agreement was signed for CAN10, which would provide the drug product needed to conduct toxicology studies as well as the first clinical study. So far, all activities related to development of a manufacturing process have been performed according to plan. This includes cell line development, manufacturing of initial small-scale productions, adaptation of the manufacturing process to medium-scale production, and formulation development. In addition, sufficient amounts of CAN10 for toxicology studies has been produced. Importantly, high yields of the antibody have been obtained in the initial productions and the generated drug product has good stability, suggesting a long shelf-life. Thereby, several risks related to manufacturing of CAN10 have been mitigated.